Reviparin
Clinical data | |
---|---|
ATC code | |
Identifiers | |
CAS Number | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
WikiDoc Resources for Reviparin |
Articles |
---|
Most recent articles on Reviparin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Reviparin at Clinical Trials.gov Clinical Trials on Reviparin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Reviparin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Reviparin Discussion groups on Reviparin Directions to Hospitals Treating Reviparin Risk calculators and risk factors for Reviparin
|
Healthcare Provider Resources |
Causes & Risk Factors for Reviparin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Reviparin is an antithrombotic in the heparin group.
External Links
- reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
- Yusuf S, Mehta SR, Xie C; et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Drug
- Cardiovascular Drugs
- Anticoagulants